IP Library Granted Patent US 9,517,993
Granted Patent B2
US 9,517,993 · App. 14/417,676 · Granted Dec 13, 2016

Antagonists of the toll-like receptor 1/2 complex

Inventors: Hang Yin (Boulder, CO); Kui Cheng (Boulder, CO)
Assignee: The Regents of the University of Colorado, a body corporate
C07C49/747C07C49/755C07C62/38C07C69/21C07C69/757C07C235/82C07D307/93C07C2102/12
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,517,993
App. No.
14/417,676
Granted
Dec 13, 2016
Kind
B2
Abstract

Provided are compounds, compositions and methods for treating Toll-like receptor 1/2 complex (TLRI/2) related inflammatory disorders. Small molecules, based on the benzotropolone scaffold, capable of influencing downstream signaling are disclosed as well as methods of making and modifying these molecules. Also provided are methods for treating a subject for a clinical condition associated with Toll-like receptor complex 1/2 activation, comprising administering to the subject an effective amount of a benzotropolone compound.

Claims (14)

1. A compound having the chemical structure:

or a pharmaceutically acceptable salt thereof.

2. A compound having the chemical structure:

or a pharmaceutically acceptable salt thereof.

3. A compound having the chemical structure:

or a pharmaceutically acceptable salt thereof.

4. A compound having the chemical structure:

or a pharmaceutically acceptable salt thereof.

5. A compound having the chemical structure:

or a pharmaceutically acceptable salt thereof.

6. A compound having the chemical structure:

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising a compound of claims 1 , 2 , 3 , 4 , 5 , or 6 , or a salt thereof, and a pharmaceutically acceptable excipient.

8. A method for treating a clinical condition associated with signaling mediated by TLR1/2 comprising administering to a subject in need of such a treatment a therapeutically effective amount of a compound of any one of claims 1 - 6 , wherein the clinical condition is psoriasis or acne vulgaris.

Assignments (2)
CONFIRMATORY LICENSE Recorded Jul 7, 2016
From: UNIVERSITY OF COLORADO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 039277/0472 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2015
From: YIN, HANG; CHENG, KUI
To: THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Reel/Frame 036143/0952 →
Continuity (2)
Provisional Application 61676992 · Jul 29, 2012
Related Publication 20150251987A1 · Sep 10, 2015